Outgoing President's Update - August 2010

JRCDear Members,

The consequences of success will be the theme for the Presidential Plenary session in Vancouver on August 18th. The time for proclaiming transplantation as the modern miracle has long passed, as we implement an increasingly standardised clinical care for around 100,000 people each year, across about 80 countries. Success of this therapy is excellent in the short term and the need for enhanced access to transplantation is now driven by the ever increasing numbers of people with treatable disease and not by enthusiast transplant centres in high technology hospitals.

It is a time for re-evaluation. The WHO has reviewed and revised its focus on transplantation equity and care of the individual remain, but there is renewed attention to quality, safety, transparency and privacy. Science graduates flocking to Transplantation as an outlet for translation of their ingenuity for the benefit of mankind, have reviewed success in transplantation and are now turning to the potentially more challenging fields of cancer and stem cell biology. The pharmaceutical and medical device industries are looking at our short term success rates and wondering how they can deliver proof of benefit from new approaches. We have seen the dreadful consequences of the rich seeking application of our therapeutic success for themselves, at the cost of health and welfare of the poor and vulnerable in our world. Governments are looking at the cost of transplantation and wondering how they can deliver the money, workforces and infrastructure required to enhance transplantation services.

We will hear from those in science at the highest levels delivering their views of where we have been and where we must go to learn from the success we have achieved and build on the consequences of that success. We will hear of the changes made by governments working together and the international momentum to manage disease treatable by transplantation in a comprehensive manner.

I write my last newsletter to the Society with my thanks for all that have supported the efforts of the last two years: Council and Officers of TTS; the Director of Medical Affairs; the Director of Society Operations and her staff; our important relationships with the officers of the WHO, the section Presidents and their councils; TTS committee chairs and their members; the Declaration of Istanbul Custodian group; Country Affiliate Presidents and their councils; and certainly not least our industry partners. The list is a long testament to our common cause. I must pay tribute to my family and colleagues who have tolerated, with remarkably good grace, stepping in at short notice to fill whatever gaps I have left behind in Australia. I note that my email count for the last couple of years has just topped 65,000 and I am sure that I must have tortured a similar number of people with my communications.Thank you for sending them and thank you for reading them.

There are many consequences of success in transplantation and I am confident that the many strengths of The Transplantation Society and the constantly renewing leadership will provide us all the capacity that will be needed.

With my best wishes,

Jeremy R. Chapman
Past President
The Transplantation Society
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi